The AI-driven bioengineering sector is experiencing rapid evolution, significantly affecting life sciences and drug development. Key players such as Ginkgo Bioworks and Recursion Pharmaceuticals are leveraging advanced technologies, with Ginkgo reporting $478 million in revenues for 2023 and Recursion conducting over 50 million experiments annually.
Published on February 9, 2026, a report by Precedence Research outlines how AI is replacing traditional methodologies in bioengineering. Companies can now process millions of protein sequences and screen billions of compounds more efficiently. Funding from various government programs globally has also fueled this transformation, providing billions aimed at enhancing AI capabilities.
Among the innovations, Ginkgo operates over 124 active programs, achieving more than 50,000 strain designs each year. Meanwhile, Insilico Medicine and Exscientia are making headway in drug development, generating numerous AI-driven candidates, with several advancing through clinical trials. This trend underscores the growing reliance on AI to accelerate drug discovery timelines.